Oramed Pharmaceuticals Inc Quick Ratio (ORMP) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Oramed Pharmaceuticals Inc  (NASDAQ: ORMP)

Oramed Pharmaceuticals Inc's Quick Ratio

ORMP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 1 a new company low.

Within Major Pharmaceutical Preparations industry 347 other companies have achieved higher Quick Ratio than Oramed Pharmaceuticals Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1025 to 1805.

Explain Quick Ratio?
How much Cash & cash equivalents ORMP´s has?
What are ORMP´s Current Liabilities?




ORMP Quick Ratio (Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
(Jun 30 2025)
Q2
Y / Y Current Liabilities Change 334.44 % 98.89 % 105.21 % 16.04 % -1.07 %
Y / Y Cash & cash equivalent Change -60.19 % -3.72 % -44.9 % -57.01 % -73.54 %
Quick Ratio MRQ 1 2.77 5.55 10 10.94
ORMP's Total Ranking # 1805 # 1025 # 273 # 228 #
Seq. Current Liabilities Change 51.89 % -5.88 % 83.41 % 65.69 % -30.47 %
Seq. Cash & cash equivalent Change -45.01 % -53.06 % 1.91 % 51.36 % 32.96 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 348
Healthcare Sector # 621
Overall Market # 1805


Quick Ratio Statistics
High Average Low
140.77 15.68 1
(Jun 30 2023)   (Jun 30 2026)




Financial Statements
Oramed Pharmaceuticals Inc's Current Liabilities $ 16 Millions Visit ORMP's Balance sheet
Oramed Pharmaceuticals Inc's Cash & cash equivalent $ 16 Millions Visit ORMP's Balance sheet
Source of ORMP's Sales Visit ORMP's Sales by Geography


Cumulative Oramed Pharmaceuticals Inc's Quick Ratio

ORMP's Quick Ratio for the trailling 12 Months

ORMP Quick Ratio

(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
(Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 122.57 % 59.7 % -45.15 % -78.51 % -89.76 %
Y / Y Cash & cash equivalent TTM Growth -48.24 % -55.95 % -66.77 % -66.4 % -54.24 %
Quick Ratio TTM 3.84 6.11 7.38 11.9 16.52
Total Ranking TTM # 3780 # 3646 # 2569 # 2418 #
Seq. Current Liabilities TTM Growth 39.09 % 19.93 % 27.94 % 4.28 % -0.2 %
Seq. Cash & cash equivalent TTM Growth -12.59 % -0.58 % -20.72 % -24.87 % -25.61 %


On the trailing twelve months basis Due to jump in Current Liabilities in the Q2 2026 to $16.04 millions, cumulative Quick Ratio decreased to 3.84 below the Oramed Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 428 other companies have achieved higher Quick Ratio than Oramed Pharmaceuticals Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3646 to 3780.

Explain Quick Ratio?
How much Cash & cash equivalents ORMP´s has?
What are ORMP´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 429
Healthcare Sector # 874
Within the Market # 3780


trailing twelve months Quick Ratio Statistics
High Average Low
36.21 12.5 3.63
(Jun 30 2023)   (Jun 30 2026)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Scienture Holdings Inc   2.71 $ 8.188  Millions$ 3.026  Millions
Acadia Pharmaceuticals Inc   2.65 $ 956.474  Millions$ 361.436  Millions
Edesa Biotech Inc   2.63 $ 10.300  Millions$ 3.910  Millions
Hepion Pharmaceuticals Inc   2.63 $ 1.629  Millions$ 0.620  Millions
Stoke Therapeutics Inc   2.62 $ 110.004  Millions$ 41.930  Millions
Elicio Therapeutics Inc   2.55 $ 23.480  Millions$ 9.202  Millions
Adc Therapeutics Sa  2.54 $ 219.107  Millions$ 86.332  Millions
Beone Medicines Ltd   2.50 $ 5,290.368  Millions$ 2,119.187  Millions
Ironwood Pharmaceuticals inc   2.41 $ 79.127  Millions$ 32.854  Millions
Schrodinger Inc   2.38 $ 413.739  Millions$ 173.845  Millions
Insmed Inc  2.37 $ 1,160.312  Millions$ 490.508  Millions
Biovie Inc   2.37 $ 8.977  Millions$ 3.796  Millions
Tao Synergies Inc   2.30 $ 2.368  Millions$ 1.032  Millions
Madrigal Pharmaceuticals Inc   2.24 $ 839.419  Millions$ 374.204  Millions
Rockwell Medical inc   2.23 $ 24.936  Millions$ 11.174  Millions
Ars Pharmaceuticals Inc   2.22 $ 143.845  Millions$ 64.728  Millions
Alnylam Pharmaceuticals Inc   2.19 $ 3,308.147  Millions$ 1,512.513  Millions
Xeris Biopharma Holdings Inc   2.16 $ 243.494  Millions$ 112.826  Millions
Ardelyx inc   2.13 $ 281.830  Millions$ 132.220  Millions
Oragenics Inc   2.12 $ 3.864  Millions$ 1.822  Millions
Pacira Biosciences inc   2.06 $ 251.031  Millions$ 122.011  Millions
Genelux Corporation  2.05 $ 29.870  Millions$ 14.590  Millions
Opko Health Inc   2.01 $ 300.761  Millions$ 149.367  Millions
Corcept Therapeutics Inc  2.00 $ 308.197  Millions$ 153.802  Millions
Clene Inc   2.00 $ 9.700  Millions$ 4.852  Millions
Blue Water Vaccines Inc  2.00 $ 5.942  Millions$ 2.974  Millions
Vertex Pharmaceuticals Inc  1.99 $ 7,852.400  Millions$ 3,937.900  Millions
Metavia Inc   1.99 $ 12.636  Millions$ 6.346  Millions
Connect Biopharma Holdings Limited  1.93 $ 31.500  Millions$ 16.301  Millions
Amarin Corp Plcuk  1.92 $ 314.850  Millions$ 164.195  Millions

Date modified: 2026-08-14T05:15:54+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.